Dear Editor, Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disorder of the central nervous system that preferentially affects the optic nerve, spinal cord, and area postrema. 1 The serum anti-aquaporin-4 antibody (anti-AQP-4 antibody) is specific for NMOSD. There are only a few reports of NMOSD presenting in the context of paraneoplastic neurological syndromes. Here we report a young woman who developed recurrent NMOSD in the setting of a lung adenocarcinoma.
Three months after presenting with myelitis she experienced a painful visual disturbance in the left eye. An examination revealed bilateral papilledema and a visual field defect of the lower quadrant in the left eye. The visual acuity of her left eye was finger counting at 50 cm. Orbit MRI revealed an enlarged bilateral optic nerve with segmental enhancement of the left optic nerve ( Fig. 1D and E) . Optic neuritis was diagnosed. At this time her cancer was stable with gefitinib treatment. She was treated with another steroid pulse therapy (daily intravenous infusion of 1 g of methylprednisolone for 5 days), followed by a tapering course of oral prednisolone as for the previous myelitis. In addition, azathioprine was added at 150 mg daily [2.5 mg/kg body weight (60 kg)]. At 8 months after presenting with optic neuritis she was taking 5 mg of prednisolone and 150 mg of azathioprine daily. At 1 month after presenting with JCN optic neuritis her visual acuity recovered to 0.7. At the latest follow up, which was performed 8 months after presenting with optic neuritis, she remained relapse-free with an EDSS score of 3.5.
Immunohistochemistry of formalin-fixed paraffin-embedded slides of the patient's neck lymph nodes showed positivity for membranous AQP-4 immunoreactivity in the cluster of the metastatic carcinoma [anti-AQP4 antibody (A5971, Sigma-Aldrich, St. Louis, MO, USA)] (Fig. 1F) .
Paraneoplastic NMOSD has been reported recently, 2 with some studies showing AQP-4 expression in the actual tumor cells.
3,4 AQP-4 may have role in tumor progression, invasion, and metastasis. 5 However, the pathophysiology underlying paraneoplastic NMOSD remains to be elucidated.
Combined treatment of anticancer therapy and an immunosuppressive agent usually results in paraneoplastic NMOSD that is episodic. 3, 6 One recurrent case occurred under the circumstance of cancer relapse. 7 However, in our patient the NMOSD recurred in spite of combined treatment and relatively stable cancer. Therefore, the clinician should keep the possibility of recurrence in mind, and might consider additive immunosuppressive treatment upon the recurrence of paraneoplastic NMOSD.
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